tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Amgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next
PremiumCompany AnnouncementsAmgen’s TEPEZZA Dosing Study Reaches Completion: What Investors Should Watch Next
14d ago
Amgen: Durable Growth from Core Franchises and High‑Value MariTide Catalysts Support Buy Rating
Premium
Ratings
Amgen: Durable Growth from Core Franchises and High‑Value MariTide Catalysts Support Buy Rating
16d ago
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
16d ago
Private Markets: Anthropic raising $10B at $350B valuation
PremiumThe FlyPrivate Markets: Anthropic raising $10B at $350B valuation
20d ago
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
Premium
Company Announcements
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
21d ago
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
Premium
Company Announcements
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
22d ago
Amgen acquires Dark Blue Therapeutics in deal valued at up to $840M
PremiumThe FlyAmgen acquires Dark Blue Therapeutics in deal valued at up to $840M
23d ago
MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’
Premium
Market News
MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’
1M ago
Amgen’s Pediatric Inebilizumab Study Signals Long-Term Upside in Rare Autoimmune Disease
Premium
Company Announcements
Amgen’s Pediatric Inebilizumab Study Signals Long-Term Upside in Rare Autoimmune Disease
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100